CliffBio
biologic

Zirabev

bevacizumab-bvzr

Loss of exclusivity—loss of exclusivity
CompanyPfizer →See this company's full patent-cliff portfolio

Drug detail

Brand nameZirabev
Active ingredientbevacizumab-bvzr
Strength100MG/4ML (25MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalJune 2019
Marketing statusRx

More from Pfizer

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

Zirabev patent cliff — loss of exclusivity — | CliffBio